Showing 12,541 - 12,560 results of 47,536 for search '(( 50 ((we decrease) OR (a decrease)) ) OR ( 5 ((fold decrease) OR (mean decrease)) ))', query time: 1.30s Refine Results
  1. 12541
  2. 12542
  3. 12543
  4. 12544

    A R13A point mutation in C4 attenuates CLCuMuV infection. by Asigul Ismayil (5698946)

    Published 2018
    “…<i>eIF4α</i> was used as an internal control. Values represent means ± SE from three independent experiments. <b>(C)</b> The mutant CLCuMuV carrying C4<sup>R13A</sup> (CLCuMuV-C4<sup>R13A</sup>), which contains a R13A mutation in <i>C4</i>, showed the decreased viral symptom compared to wild type CLCuMuV. …”
  5. 12545
  6. 12546
  7. 12547
  8. 12548

    CD44v6 is required for the growth of BTSC in CD44<sup>high</sup> GBM. by Mayumi Jijiwa (207098)

    Published 2011
    “…B: Treatment with siRNA decreased the expression of CD44v6 in both neurosphere (left panel) and serum-propagated CD44<sup>high</sup> GBM (middle panel). …”
  9. 12549
  10. 12550
  11. 12551

    Spatial expression pattern of proBcMF26a: GUS-GFP. by Meiling Lyu (767333)

    Published 2015
    “…<p>(A–L) Histochemical GUS assays of the T<sub>2</sub><i>Arabidopsis</i> transformed with pBGWFS7.0–proBcMF26a: GUS-GFP vector. …”
  12. 12552
  13. 12553
  14. 12554

    Infidelity of SARS-CoV Nsp14-Exonuclease Mutant Virus Replication Is Revealed by Complete Genome Sequencing by Lance D. Eckerle (249310)

    Published 2010
    “…We report here the engineering and recovery of nsp14-ExoN mutant viruses of severe acute respiratory syndrome coronavirus (SARS-CoV) that have stable growth defects and demonstrate a 21-fold increase in mutation frequency during replication in culture. …”
  15. 12555

    The Toll-Like Receptor 5 Agonist Entolimod Mitigates Lethal Acute Radiation Syndrome in Non-Human Primates by Vadim I. Krivokrysenko (795689)

    Published 2015
    “…Following exposure to LD<sub>50-70/40</sub> of radiation, injection of efficacious doses of entolimod administered as late as 25 hours thereafter reduced the risk of mortality 2-3-fold, providing a statistically significant (P<0.01) absolute survival advantage of 40–60% compared to vehicle treatment. …”
  16. 12556
  17. 12557
  18. 12558
  19. 12559
  20. 12560